Glucosamine sulfate suppresses the expression of matrix metalloproteinase-3 in osteosarcoma cells in vitro

Pohlig, Florian; Ulrich, Jörg; Lenze, Ulrich; Mühlhofer, Heinrich; Harrasser, Norbert; Suren, Christian; Schauwecker, Johannes; Mayer‐Kuckuk, Philipp; Eisenhart-Rothe, Rüdiger von

doi:10.1186/s12906-016-1315-6

Cited by 12 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Matrix metalloproteinases (MMPs) are enzymes known to degrade the ECM, and 23 types have been reported in humans [46]. Of these enzymes, MMP-1, -2, -3, -8, -9, -13, and -14 have been reported to be involved in promoting the migration and infiltration of osteosarcoma cells [47,48,49,50,51,52,53,54]. The substrate of MMP-1, -8, and -13 is type I collagen, and that of MMP-2, -3, -9, and -13 is type IV collagen, and furthermore, laminin is another substrate of MMP-2, -3, and -14.…”

Section: Aberrant Expression Of Mirna Related To Invasion and Metamentioning

confidence: 99%

MicroRNA-Based Diagnosis and Treatment of Metastatic Human Osteosarcoma

Sasaki

Osaki

Okada

2019

Cancers

View full text Add to dashboard Cite

Osteosarcoma is a malignant tumor of the bones that commonly occurs in young individuals. The 5-year survival rate of osteosarcoma patients is 60–70%. Metastasis to the lungs leads to death in 30–40% of osteosarcoma patients. Therefore, the development of effective strategies for early detection and treatment of this disease are important to improve the survival of osteosarcoma patients. However, metastatic markers for osteosarcoma and molecules that might be targeted for the treatment of metastatic osteosarcoma have not been identified yet. Therefore, the mechanism of metastasis to the lungs needs to be explored from a novel viewpoint. Recently, the aberrant expression of microRNAs (miRNAs) has been reported to be involved in the carcinogenesis and cancer progression of many cancers. Furthermore, miRNAs in the blood have been reported to show an aberrant expression unique to several cancers. Therefore, miRNAs are gaining attention as potential diagnostic markers for cancers. On the other hand, normalizing the dysregulated expression of miRNAs in cancer cells has been shown to alter the phenotype of cancer cells, and thus treatment strategies targeting miRNAs are also being considered. This review summarizes the abnormality of miRNA expression associated with the metastasis of osteosarcoma and describes the present situation and issues regarding the early diagnosis and development of treatment strategies for metastatic osteosarcoma based on the current understanding of this disease.

show abstract

Section: Aberrant Expression Of Mirna Related To Invasion and Metamentioning

confidence: 99%

MicroRNA-Based Diagnosis and Treatment of Metastatic Human Osteosarcoma

Sasaki

Osaki

Okada

2019

Cancers

View full text Add to dashboard Cite

show abstract

“…Therefore, we also confirmed the reliability of our candidate drugs by consulting the relevant literature in PubMed. Glucosamine, which is a common dietary supplement, has immunosuppressive effects on autoimmune diseases [34,35]. Chien et al confirmed Glucosamine could reduce IL2 downstream signaling through downregulating IL2RA [36], while IL2 and IL2RA ( CD25 ) were upregulated in patients with MG, and IL2RA might affect the clinical symptoms of MG [37,38].…”

Section: Resultsmentioning

confidence: 99%

Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis

Cao

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

Myasthenia gravis (MG) is an autoimmune disease. In recent years, considerable evidence has indicated that Gene Ontology (GO) functions, especially GO-biological processes, have important effects on the mechanisms and treatments of different diseases. However, the roles of GO functions in the pathogenesis and treatment of MG have not been well studied. This study aimed to uncover the potential important roles of risk-related GO functions and to screen significant candidate drugs related to GO functions for MG. Based on MG risk genes, 238 risk GO functions and 42 drugs were identified. Through constructing a GO function network, we discovered that positive regulation of NF-kappaB transcription factor activity (GO:0051092) may be one of the most important GO functions in the mechanism of MG. Furthermore, we built a drug-GO function network to help evaluate the latent relationship between drugs and GO functions. According to the drug-GO function network, 5 candidate drugs showing promise for treating MG were identified. Indeed, 2 out of 5 candidate drugs have been investigated to treat MG. Through functional enrichment analysis, we found that the mechanisms between 5 candidate drugs and associated GO functions may involve two vital pathways, specifically hsa05332 (graft-versus-host disease) and hsa04940 (type I diabetes mellitus). More interestingly, most of the processes in these two pathways were consistent. Our study will not only reveal a new perspective on the mechanisms and novel treatment strategies of MG, but also will provide strong support for research on GO functions.

show abstract

“…Pohlig et al. found a pronounced suppressive effect of glucosamine sulfate particularly on MMP‐3 and ‐9 mRNA and protein levels in OS cell lines in vitro . Hirahata et al.…”

Section: Targeting Mmps: Prospects In Clinical Applicationmentioning

confidence: 98%

Pathological and therapeutic aspects of matrix metalloproteinases: Implications in osteosarcoma

Tang¹,

Tang²,

Jiang³

et al. 2019

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Osteosarcoma (OS) is one of the most common malignant bone tumors in children and adolescents, and the eighth leading form of childhood cancer. Matrix metalloproteinases (MMPs) are proteolytic enzymes implicated in certain cancers including OS. In this review, we discuss the mechanism of actions of MMPs in progression of OS, and the therapeutic use of MMPs inhibitors in the treatment of OS with subsequent clinical studies and future management. The expression of MMPs is upregulated in cancer cells by a variety of cytokines and growth factors, and upregulation of MMPs induces degradation of the extracellular matrix that contributes to cell proliferation by releasing growth factors. MMPs promote the detachment and migration of endothelial cells, cross the basement membrane as well as invade the surrounding lymphatic vessels and causes cancer metastasis. The use of selective MMP inhibitors with limited side effects might be promising therapeutic strategy in the treatment of OS. More clinical trials are necessary to evaluate the role of selective MMPs inhibitors in the prevention and treatment of OS along with their assessment of toxicity.

show abstract

Glucosamine sulfate suppresses the expression of matrix metalloproteinase-3 in osteosarcoma cells in vitro

Cited by 12 publications

References 26 publications

MicroRNA-Based Diagnosis and Treatment of Metastatic Human Osteosarcoma

MicroRNA-Based Diagnosis and Treatment of Metastatic Human Osteosarcoma

Building the drug-GO function network to screen significant candidate drugs for myasthenia gravis

Pathological and therapeutic aspects of matrix metalloproteinases: Implications in osteosarcoma

Contact Info

Product

Resources

About